- Home
- IQI vs VNDA Comparison
IQI vs VNDA Comparison
Compare IQI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IQI | VNDA |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.3M | 474.0M |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | IQI | VNDA |
|---|---|---|
| Price | $10.03 | $8.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 134.1K | ★ 3.6M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.50 |
| Revenue Next Year | N/A | $38.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $8.86 | $3.81 |
| 52 Week High | $10.42 | $9.60 |
Technical Indicators
Market Signals| Indicator | IQI | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 59.84 |
| Support Level | $9.85 | $4.25 |
| Resistance Level | $10.05 | $9.35 |
| Average True Range (ATR) | 0.08 | 0.56 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 16.90 | 86.31 |
Price Performance
Historical ComparisonAbout IQI Invesco Quality Municipal Income Trust
Invesco Quality Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide current income which is exempt from federal income tax.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.